The hidden reason cancer immunotherapy often fails

Cancer immunotherapy has been a game-changer, but many tumors still find ways to slip past the immune system. New research reveals a hidden trick: cancer cells can package the immune-blocking protein PD-L1 into tiny particles that circulate through the body and weaken immunotherapy’s impact. Scientists in Japan discovered that a little-known protein, UBL3, controls this process—and surprisingly, common cholesterol-lowering drugs called statins can shut it down.


Scientists discovered how cancer cells secretly spread immune-blocking signals using tiny vesicles filled with PD-L1. Even more surprising, widely used statins can disrupt this process, potentially making immunotherapy far more effective. Credit: Shutterstock.

New Scientists Awards - NOMINATION OPEN NOW!

#worldresearchawards #researcherawards #academicawards #scienceawards #globalresearchawards #phd #researcher #NewScientistsAwards #NSCAwards #CancerImmunotherapy #TumorMicroenvironment #ImmuneEvasion #PD1 #PDL1 #CheckpointInhibitors #CancerResistance #PrecisionOncology #ImmunoOncology #TumorHeterogeneity

Comments

Popular posts from this blog

🏆Global Excellence in Research Award #sciencefather #researcher #phd #nscawards #ExcellenceResearch

🌞Butterfly Hole” in the Sun Could Spark Dazzling Auroras on Earth #sciencefather #researcher #nasa

🏅Global Lifetime Achievement Award in Research & Innovation #sciencefather #nscawards #phd